Iovance Biotherapeutics Inc (OQ:IOVA)

Business Focus: Bio Diagnostics & Testing

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Tel: N/A
IR: See website
Key People
Frederick G. Vogt
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Jean-Marc Bellemin
Chief Financial Officer
Igor P. Bilinsky
Chief Operating Officer
Friedrich Graf Finckenstein
Chief Medical Officer
Business Overview
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company, which commercializes autologous T-cell therapy to address solid tumor cancer. It develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, lifileucel, is being developed in advanced, or metastatic or unresectable, melanoma, as well as in other indications. Lifileucel is investigated in two consecutive cohorts in a clinical trial of advanced melanoma patients post-anti-PD-1 therapy, including in a prospectively defined pivotal cohort. It has initiated Phase III clinical trial of lifileucel in combination with pembrolizumab, TILVANCE-301. The Company is also pursuing registrational strategies for lifileucel in advanced cervical cancer and for its TIL therapy, LN-145, in metastatic non-small cell lung cancer. Its first genetically modified, PD-1 inactivated TIL therapy, IOV-4001, is under Phase I/II clinical trial, IOV-GM1-201.
Financial Overview
For the fiscal year ended 31 December 2023, Iovance Biotherapeutics Inc revenues increased from $0K to $1.2M. Net loss increased 12% to $444M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 26% to $309.2M (expense), General & Administrative - Balancing increase of 13% to $79.2M (expense).
Employees: 557 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $4,411M as of Dec 31, 2023
Annual revenue (TTM): $1.19M as of Dec 31, 2023
EBITDA (TTM): -$439.06M as of Dec 31, 2023
Net annual income (TTM): -$444.04M as of Dec 31, 2023
Free cash flow (TTM): -$384.11M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 278,847,679 as of Feb 22, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.